NHS guidelines on familial breast cancer care:
This article was originally published in Clinica
Executive Summary
Breast cancer care in England and Wales is subject to new guidelines on the provision of mammography, genetic testing and risk-reducing surgery in cases of so-called "familial" risk. Mammography should be performed subject to clearly advising the patient on the implications of early detection, the National Institute for Clinical Excellence (NICE) and the National Collaborating Centre for Primary Care (NCCPC) recommend. They also urge the NHS to recognise that genetic testing and risk-reducing surgery are appropriate in only a small proportion of women from high-risk families. The guidance also highlights the need for greater public awareness of risk, notably that the great majority of women with a family history do not fall into a high-risk category.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.